Skip to main content
Matthew Ingham, MD, Oncology, New York, NY, New York-Presbyterian Hospital

MatthewAInghamMD

Oncology • New York, NY

Physician

Request Appointment

Overview of Dr. Ingham

Dr. Matthew Ingham is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from UMass Chan Medical School and has been in practice 7 years. He is one of 369 doctors at New York-Presbyterian Hospital and one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 20 publications and over 500 citings.

Education & Training

  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 2010 - 2013
  • University of Massachusetts Medical School
    University of Massachusetts Medical SchoolClass of 2010

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2013 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Three Presentations at Key Upcoming Clinical Oncology Conferences in November
    Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Three Presentations at Key Upcoming Clinical Oncology Conferences in NovemberNovember 1st, 2022
  • Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
    Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingNovember 13th, 2021
  • Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid Tumors
    Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid TumorsJune 2nd, 2021

Hospital Affiliations

Dr. Matthew Ingham, Dr. Matthew Ingham, MD, Dr. M Ingham, Dr. Matthew A Ingham